Review of the Relationship between Anti-Hypertensive and Anti-Diabetes Drugs with Psychiatric Disorders
Novelty in Biomedicine,
Vol. 13 No. 3 (2025),
27 July 2025
,
Page 184-190
https://doi.org/10.22037/nbm.v13i3.47690
Abstract
Background: Diabetes and hypertension are two common diseases all over the world. There are several treatment options for the management of these diseases. Some studies have reported that drugs used to manage diabetes and hypertension may have an impact on psychiatric disorders such as depression and dementia. In this article, we aimed to review the results of recent studies about the impact of anti-hypertensive and antidiabetic drugs on psychiatric disorders.
Materials and Methods: We reviewed studies with keywords of “diabetes”, OR “diabetic”, OR “anti-diabetes”, OR “anti-diabetes”, OR “antidiabetic”, AND “drug”, OR “hypertension”, OR “hypertensive”, OR “anti-hypertension”, OR “anti-hypertensive”, OR “anti-hypertensive”, AND “psychology”, OR “psychological” in PUBMED, ELSEVIER, and CENTRAL databases from 2015 to 2025.
Results: The results of the studies were contradictory. There was no consensus idea about antidiabetic drugs, but it seems that sodium-glucose cotransporter two inhibitors can reduce the risk of depression and dementia. The results of studies about anti-hypertensive drugs had more similarities, and some anti-hypertensive drugs, like angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers, may reduce the risk of psychiatric disorders.
Conclusion: There is a strong need for evaluation of the effects of anti-hypertensive and antidiabetic drugs on psychiatric disorders because the results of current studies are discrepant.
- Anti-hypertensive
- Antidiabetics
- Drug
- Psychiatry
- Mental disorders
How to Cite
References
The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nature microbiology. 2020;5(4):536-44.
Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, et al. Early laboratory preparedness of the Korea Disease Control and Prevention Agency and response to unknown pneumonia outbreak from Wuhan, China, in January 2020. Annals of Laboratory Medicine. 2021 Nov 1;41(6):532-9.
Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, et al. Presumed asymptomatic carrier transmission of COVID-19. Jama. 2020 Apr 14;323(14):1406-7.
Van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. New England journal of medicine. 2020 Apr 16;382(16):1564-7.
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. New England journal of medicine. 2020 Feb 20;382(8):727-33.
Li Y, Zhou W, Yang L, You R. Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor. Pharmacological research. 2020;157:104833.
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. cell. 2020 Apr 16;181(2):271-80.
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. New England journal of medicine. 2020 Apr 30;382(18):1708-20.
Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Science China Life Sciences. 2020 Mar;63(3):457-60.
Nicastri E, D’Abramo A, Lepore L, Maffongelli G, Bartoli TA, Vita S, et al. The evolution of clinical and scientific evidence-based management guidelines for Covid-19 disease: A longitudinal descriptive analysis. Available at SSRN 3672327. 2020 Oct 8.
Pau AK, Aberg J, Baker J, Belperio PS, Coopersmith C, Crew P, et al. Convalescent plasma for the treatment of COVID-19: perspectives of the National Institutes of Health COVID-19 treatment guidelines panel. Annals of internal medicine. 2021 Jan;174(1):93-5.
Health NIo. National Institutes of Health COVID-19 treatment guidelines. Therapeutic Management of Nonhospitalized Adults With COVID. 2021;19.
Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The lancet. 2020 Feb 22;395(10224):565-74.
Ponce M, Sankari A, Sharma S. Pulmonary Function Tests. 2022 Sep 3. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2023.
Contini M, Conte E, Agostoni P. Lung function evaluation in heart failure: possible pitfalls. Breathe. 2020;16(1).
Borg BM, Osadnik C, Adam K, Chapman DG, Farrow CE, Glavas V, et al. Pulmonary function testing during SARS‐CoV‐2: An ANZSRS/TSANZ position statement. Respirology. 2022 Sep;27(9):688-719..
Wainstein EJ, Peroni HJ, Ferreyro BL, Staneloni MI, Marcos MG, Wolfgor A, et al. Incidence of COVID-19 after pulmonary function tests: a retrospective cohort study. Revista de la Facultad de Ciencias Médicas. 2021 Dec 28;78(4):367.
Lv D, Chen X, Mao L, Sun J, Wu G, Lin Z, et al. Pulmonary function of patients with 2019 novel coronavirus induced pneumonia: a retrospective cohort study.
Polese J, Sant’Ana L, Moulaz IR, Lara IC, Bernardi JM, Lima MD, et al. Pulmonary function evaluation after hospital discharge of patients with severe COVID-19. Clinics. 2021 Jun 28;76:e2848.
Wu Q, Zhong L, Li H, Guo J, Li Y, Hou X, et al. A follow‐up study of lung function and chest computed tomography at 6 months after discharge in patients with coronavirus disease 2019. Canadian Respiratory Journal. 2021;2021(1):6692409.
van Willigen HD, Wynberg E, Verveen A, Dijkstra M, Verkaik BJ, Figaroa OJ, et al. One-fourth of COVID-19 patients have an impaired pulmonary function after 12 months of disease onset. PloS one. 2023 Sep 11;18(9):e0290893..
Suppini N, Fira-Mladinescu O, Traila D, Motofelea AC, Marc MS, Manolescu D, et al. Longitudinal analysis of pulmonary function impairment one year post-covid-19: a single-center study. Journal of Personalized Medicine. 2023 Jul 26;13(8):1190.
Toh MR, Teo YR, Poh LC, Tang Y, Soh RY, Sharma K, et al. Impact of COVID infection on lung function test and quality of life. Scientific Reports. 2023 Oct 12;13(1):17275.
Ware Jr JE, Gandek B. Overview of the SF-36 health survey and the international quality of life assessment (IQOLA) project. Journal of clinical epidemiology. 1998;51(11):903-912.
Lewis KL, Helgeson SA, Tatari MM, Mallea JM, Baig HZ, Patel NM. COVID-19 and the effects on pulmonary function following infection: A retrospective analysis. EClinicalMedicine. 2021;39.
Zhang H, Li X, Huang L, Gu X, Wang Y, Liu M, et al. Lung-function trajectories in COVID-19 survivors after discharge: a two-year longitudinal cohort study. EClinicalMedicine. 2022 Dec 1;54.
Huang L, Li X, Gu X, Zhang H, Ren L, Guo L, et al. Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study. The Lancet Respiratory Medicine. 2022 Sep 1;10(9):863-76.
Li D, Liao X, Liu Z, Ma Z, Dong J, Zheng G, et al. Healthy outcomes of patients with COVID-19 two years after the infection: a prospective cohort study. Emerging microbes & infections. 2022 Dec 31;11(1):2680-8.
Togami E, Griffith B, Mahran M, Nezu IH, Mirembe BB, Kaasik-Aaslav K, et al. The World Health Organization’s public health intelligence activities during the COVID-19 pandemic response, December 2019 to December 2021. Eurosurveillance. 2022 Dec 8;27(49):2200142..
Čivljak R, Markotić A, Kuzman I. The third coronavirus epidemic in the third millennium: what’s next? Croatian medical journal. 2020;61(6):1-4.
Catanzaro M, Fagiani F, Racchi M, Corsini E, Govoni S, Lanni C. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2. Signal transduction and targeted therapy. 2020 May 29;5(1):84..
Jacobs M, Van Eeckhoutte HP, Wijnant SR, Janssens W, Joos GF, Brusselle GG, et al. Increased expression of ACE2, the SARS-CoV-2 entry receptor, in alveolar and bronchial epithelium of smokers and COPD subjects. European Respiratory Journal. 2020 Aug 20;56(2).
Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. nature. 2020 Mar 12;579(7798):270-3..
Raut ER, Raut AR. A Review on Coronavirus Disease-A Future Challenge for Mankind (Focusing on Indian Situation). Coronaviruses. 2021;2(8):9-13.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The lancet. 2020 Mar 28;395(10229):1054-62.
Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Boletim Epidemiológico: Ministério da Saúde Brasília; 2020.
Lighter J, Phillips M, Hochman S, Sterling S, Johnson D, Francois F, et al. Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission. Clinical Infectious Diseases. 2020 Jul 28;71(15):896-7.
Rusu I, Turlacu M, Micheu MM. Acute myocardial injury in patients with COVID-19: Possible mechanisms and clinical implications. World Journal of Clinical Cases. 2022;10(3):762.
Scappaticcio L, Pitoia F, Esposito K, Piccardo A, Trimboli P. Impact of COVID-19 on the thyroid gland: an update. Reviews in endocrine and metabolic disorders. 2020:1-13.
Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nature Reviews Microbiology. 2023;21(3):133-146.
Franczuk M, Przybyłowski T, Czajkowska-Malinowska M, Radliński J, Bochenek G, Wesołowski S, et al. Spirometry during the SARS-CoV-2 pandemic: guidelines and practical advice from the expert panel of Respiratory Physiopathology Assembly of Polish Respiratory Society.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet. 2020 Feb 15;395(10223):497-506.
- Abstract Viewed: 129 times
- pdf Downloaded: 90 times